Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604-921-1810

Fax: 604-921-1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Firstvik Nov. 19 at 10:39 PM

$BCTX Where's the pumper? 😆

0 · Reply

rp6577 Nov. 19 at 7:45 PM

$BCTX I sold out in the 12s. Could be getting tempted again at these levels

0 · Reply

MarkeTimer Nov. 19 at 7:32 PM

$BCTX I believe there been four reverse stock splits on this POS 1:10 1:10 1:15 1:300 If you purchased prior to the 2014 split, your shares, give or take would be worth .... .000015

0 · Reply

ZacksResearch Nov. 19 at 5:45 PM

Big moment coming for $BCTX at SABCS 2025 🔥 BriaCell is rolling out three clinical and one preclinical posters, including two late-breaking clinical presentations — a clear signal they’re bringing meaningful data to one of the biggest breast cancer stages of the year. These posters hit on everything from Phase 3 genotype matching & biomarkers to survival results from their Phase II Bria-IMT allogenic vaccine, with all presentations set for December 10. Serious visibility boost for the company. See the complete stock outlook here👉 https://www.zacks.com/stock/quote/BCTX?cid=sm-stocktwits-0-quote_overview-oc-21732&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_21732

1 · Reply

BorATM Nov. 19 at 4:53 PM

$BCTX this stock will do the dilution and go all the way to lower than dollar one dollar and then the reverse splitting is going to be done. And all this again and again. It has good news all the time but I feel like it is controlled by some group of scammers just like many Chinese stocks.

0 · Reply

2maligators Nov. 19 at 3:42 PM

$BCTX wtf geez

0 · Reply

Kirubin Nov. 19 at 3:41 PM

$BCTX where are the idiot pumpers…? MORONS

0 · Reply

JJBurch Nov. 19 at 10:34 AM

$BCTX $KZIA $IXHL I’ve been deeply invested and supporting these three bios for years I’ve put most of my money into them THIS year All three are going to make me very wealthy All three are blockbusters.

1 · Reply

Kirubin Nov. 18 at 8:56 PM

$BCTX buy garbage it is worth more!🥶

0 · Reply

Firstvik Nov. 18 at 8:44 PM

$BCTX 🏃‍♀️ don't 🚶‍♂️ from this dumpster 🔥

2 · Reply

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 12 days ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 15 days ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 22, 2025, 7:30 AM EDT - 4 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Oct 21, 2025, 7:50 AM EDT - 4 weeks ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 4 weeks ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 4 weeks ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 5 weeks ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 6 weeks ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 3 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 3 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 3 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 3 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 3 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 4 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 4 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 4 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 4 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 4 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 4 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 4 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 4 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 4 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 4 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 5 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 5 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 6 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 6 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 6 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 6 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 7 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 7 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 7:30 AM EDT - 7 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 24, 2025, 8:00 PM EDT - 7 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 10:11 AM EDT - 7 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 7:30 AM EDT - 7 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 23, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 22, 2025, 7:30 AM EDT - 7 months ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 16, 2025, 7:30 AM EDT - 7 months ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 8 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Mar 20, 2025, 8:00 AM EDT - 8 months ago

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

Feb 5, 2025, 6:15 PM EST - 10 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Feb 5, 2025, 4:05 PM EST - 10 months ago

BriaCell Therapeutics Announces Closing of Public Offering

Feb 3, 2025, 7:59 PM EST - 10 months ago

BriaCell Therapeutics Announces Pricing of Public Offering

Feb 3, 2025, 4:45 PM EST - 10 months ago

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

Feb 3, 2025, 7:30 AM EST - 10 months ago

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Jan 27, 2025, 6:42 PM EST - 10 months ago

BriaCell Announces Completion of 15:1 Share Consolidation

Jan 3, 2025, 5:05 PM EST - 11 months ago

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

Dec 17, 2024, 4:05 PM EST - 1 year ago

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

Firstvik Nov. 19 at 10:39 PM

$BCTX Where's the pumper? 😆

0 · Reply

rp6577 Nov. 19 at 7:45 PM

$BCTX I sold out in the 12s. Could be getting tempted again at these levels

0 · Reply

MarkeTimer Nov. 19 at 7:32 PM

$BCTX I believe there been four reverse stock splits on this POS 1:10 1:10 1:15 1:300 If you purchased prior to the 2014 split, your shares, give or take would be worth .... .000015

0 · Reply

ZacksResearch Nov. 19 at 5:45 PM

1 · Reply

BorATM Nov. 19 at 4:53 PM

0 · Reply

2maligators Nov. 19 at 3:42 PM

$BCTX wtf geez

0 · Reply

Kirubin Nov. 19 at 3:41 PM

$BCTX where are the idiot pumpers…? MORONS

0 · Reply

JJBurch Nov. 19 at 10:34 AM

1 · Reply

Kirubin Nov. 18 at 8:56 PM

$BCTX buy garbage it is worth more!🥶

0 · Reply

Firstvik Nov. 18 at 8:44 PM

$BCTX 🏃‍♀️ don't 🚶‍♂️ from this dumpster 🔥

2 · Reply

SmallCapGrowth Nov. 18 at 7:13 PM

$BCTX

1 · Reply

SmallCapGrowth Nov. 18 at 7:08 PM

Stocks on the RISE: $BCTX is set - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6802671

0 · Reply

SmallCapGrowth Nov. 18 at 6:12 PM

Daily Hot Plays : Cancer Stock News Alert: $BCTX is set to... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176961721 via @Investors_Hub

0 · Reply

Kirubin Nov. 18 at 5:26 PM

$BCTX where is this moron at?

1 · Reply

FredFlintstock Nov. 18 at 4:57 PM

$BCTX tHE MarKeT MAkeRs aRe JUst dRopPinG tHe prIcE sO tHeIr FriEnds caN gET CheAp sHarEs..🤣🤣🤣

1 · Reply

SmallCapGrowth Nov. 18 at 4:46 PM

Cancer Stock News Alert: $BCTX is set to present new clinical data at SABCS 2025 on Dec 10. Three posters total, with fresh Phase 3 biomarker and Phase 2 survival information. NEWS: https://globenewswire.com/news-release/2025/11/18/3189891/0/en/BriaCell-Selected-to-Present-Phase-2-3-Clinical-Data-at-SABCS-2025.html

0 · Reply

SmallCapGrowth Nov. 18 at 3:49 PM

MOMO'S BREAKOUT BOARD : Stocks on the RISE: $BCTX is set to pres... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176960842 via @Investors_Hub @smallcapvoice

0 · Reply

Kirubin Nov. 18 at 2:38 PM

$BCTX THIS IS CANCER itself!🥶

0 · Reply

JediGreen Nov. 18 at 2:17 PM

$BCTX

1 · Reply

SmallCapVoice Nov. 18 at 12:57 PM

BriaCell $BCTX is set to present new clinical data at SABCS 2025 on Dec 10. Three posters total, with fresh Phase 3 biomarker and Phase 2 survival information. https://www.globenewswire.com/news-release/2025/11/18/3189891/0/en/BriaCell-Selected-to-Present-Phase-2-3-Clinical-Data-at-SABCS-2025.html

0 · Reply

Thestocktraderhubzee Nov. 18 at 12:34 PM

$BCTX BriaCell Therapeutics To Present Three Clinical, One Preclinical Posters At 2025 San Antonio Breast Cancer Symposium

0 · Reply

MrTicker Nov. 18 at 12:30 PM

$BCTX https://ml.globenewswire.com/media/OWJmYTY0NDItYmZhYy00MWYxLWI1YjAtMzUyN2UyYjUwNmM1LTExMDIyMjktMjAyNS0xMS0xOC1lbg==/tiny/BriaCell-Therapeutics-Corp-.png

0 · Reply

Market Cap	15.20M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	45,600
Avg Vol	74,008
Day's Range	N/A - N/A
Shares Out	1.88M
Stochastic %K	0%
Beta	1.21
Analysts	Hold
Price Target	$40.00